Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enVVeno MedicalNVNO +1.24%26 EV-to-EBIT is 0.80 as of Aug. 15, 2026. GuruFocus rates NVNO with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 473 Medical Devices & Instruments companies, enVVeno Medical ranks better than 97.46% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
enVVeno Medical's Enterprise Value for the quarter that ended in Jun. 2026 was $-13.77 Mil.
enVVeno Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enVVeno Medical EV-to-EBIT Related Terms
enVVeno Medical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for enVVeno Medical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, enVVeno Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enVVeno Medical EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's EV-to-EBIT falls into.
enVVeno Medical's current Enterprise Value is $-13.48 Mil.
enVVeno Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enVVeno Medical (NVNO) has a EV-to-EBIT of 0.80 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on enVVeno Medical and its competitors. According to the industry distribution chart, enVVeno Medical ranks #12 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 2.5%.
Is enVVeno Medical's EV-to-EBIT too high?
enVVeno Medical's current EV-to-EBIT is 0.80. The Medical Devices & Instruments industry median EV-to-EBIT is 19.17. enVVeno Medical's value of 0.80 is 95.8% below this industry median. Based on the distribution chart, enVVeno Medical ranks #12 out of 473 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, enVVeno Medical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's EV-to-EBIT compare to CODX and HSCS?
According to the Medical Devices & Instruments industry distribution chart, enVVeno Medical ranks #12 out of 473 companies for EV-to-EBIT. This places enVVeno Medical in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.17. enVVeno Medical's value of 0.80 is 95.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.17, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enVVeno Medical's current EV-to-EBIT of 0.80 is 95.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on enVVeno Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enVVeno Medical's current EV-to-EBIT is 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNO) has a current EV-to-EBIT of 0.80. The current EV-to-EBIT is 0.80 and 95.8% below the Medical Devices & Instruments industry median of 19.17. enVVeno Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For enVVeno Medical (NVNO), the current EV-to-EBIT is 0.80 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
26GF Score
Get the complete analysis for NVNO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVNO has been successfully added to your 
